18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron
emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate
tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").